Paradigm Biocapital Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,210,774	Closed	-$103M	–	38
2025 Q4	$103M	Sell	2,210,774 -340,000	-13%	-$15.1M	2.76%	14
2025 Q3	$106M	Buy	2,550,774 +207,221	+9%	+$6.63M	3.14%	10
2025 Q2	$67.4M	Buy	2,343,553 +397,385	+20%	+$12.3M	2.88%	11
2025 Q1	$65.3M	Buy	1,946,168 +35,407	+2%	+$1.32M	3%	9
2024 Q4	$97.7M	Sell	1,910,761 -605,925	-24%	-$33.9M	3.4%	10
2024 Q3	$129M	Buy	2,516,686 +3,384	+0.1%	+$175K	4.5%	5
2024 Q2	$113M	Sell	2,513,302 -611,447	-20%	-$28.2M	4.31%	8
2024 Q1	$146M	Buy	3,124,749 +811,830	+35%	+$31.8M	5.15%	5
2023 Q4	$82.3M	Buy	2,312,919 +134,182	+6%	+$4.11M	3.86%	12
2023 Q3	$64.8M	Buy	2,178,737 +783,735	+56%	+$16.2M	4.42%	10
2023 Q2	$25.1M	Buy	1,395,002 +261,220	+23%	+$5.21M	2.03%	19
2023 Q1	$18.2M	Buy	1,133,782 +243,677	+27%	+$4.51M	1.73%	21
2022 Q4	$16.3M	Buy	890,105 +370,849	+71%	+$6.53M	1.91%	20
2022 Q3	$10.2M	Buy	+519,256	New	+$10.6M	1.44%	23